- Home
- EOLS
EOLS
Evolus Inc.
as 03-25-2025 12:32pm EST
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEWPORT BEACH |
| Market Cap: | 854.0M | IPO Year: | 2018 |
| Target Price: | $24.67 | AVG Volume (30 days): | 700.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.25 - $17.82 | Next Earning Date: | 03-04-2025 |
| Revenue: | $266,274,000 | Revenue Growth: | 31.76% |
| Revenue Growth (this year): | 34.56% | Revenue Growth (next year): | 32.26% |
Stock Insider Trading Activity of Evolus Inc. (EOLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Beaver Sandra | EOLS | Chief Financial Officer | Mar 18 '25 | Sell | $13.26 | 8,996 | $119,242.88 | 173,583 | |
| MOATAZEDI DAVID | EOLS | See Remarks | Mar 18 '25 | Sell | $13.26 | 103,376 | $1,370,248.88 | 514,870 | |
| Avelar Rui | EOLS | See Remarks | Mar 18 '25 | Sell | $13.26 | 27,904 | $369,867.52 | 362,467 | |
| Parschauer Karah Herdman | EOLS | Director | Mar 12 '25 | Sell | $12.99 | 12,888 | $167,465.38 | 32,183 |
Latest Evolus Inc. News
EOLS Breaking Stock News: Dive into EOLS Ticker-Specific Updates for Smart Investing
Business Wire
8 hours ago
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
Simply Wall St.
2 days ago
Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain
Business Wire
4 days ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
5 days ago
Evolus Insider Sold Shares Worth $1,370,249, According to a Recent SEC Filing
Motley Fool
15 days ago
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
Thomson Reuters StreetEvents
20 days ago
Q4 2024 Evolus Inc Earnings Call
GuruFocus.com
21 days ago
Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...
MT Newswires
21 days ago
Evolus Q4 Net Loss Narrows, Revenue Rises; Issues Guidance
Compare EOLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EOLS Evolus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.